Holen Sie sich die Stockscreener-App
180.30
1.97%
-3.62
Handel nachbörslich:
180.30
Schlusskurs vom Vortag:
$183.92
Offen:
$180.56
24-Stunden-Volumen:
329.59K
Relative Volume:
1.32
Marktkapitalisierung:
$5.26B
Einnahmen:
$290.51M
Nettoeinkommen (Verlust:
$89.16M
KGV:
60.30
EPS:
2.99
Netto-Cashflow:
$119.18M
1W Leistung:
-7.27%
1M Leistung:
+0.59%
6M Leistung:
-0.95%
1J Leistung:
+1.33%
1-Tages-Spanne:
$175.98
$182.08
1-Wochen-Bereich:
$175.98
$197.94
52-Wochen-Spanne:
$141.72
$219.34
Krystal Biotech Inc Stock (KRYS) Company Profile
Firmenname
Krystal Biotech Inc
Sektor
Branche
Telefon
(412) 586-5830
Adresse
2100 WHARTON STREET, PITTSBURGH, PA
Vergleichen Sie KRYS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
180.30 | 5.26B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-05 | Eingeleitet | Jefferies | Buy |
| 2024-08-06 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-12 | Eingeleitet | Citigroup | Buy |
| 2023-09-07 | Eingeleitet | Berenberg | Buy |
| 2023-04-18 | Eingeleitet | Stifel | Buy |
| 2023-02-28 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-18 | Eingeleitet | BofA Securities | Buy |
| 2021-07-20 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-18 | Eingeleitet | B. Riley FBR | Buy |
| 2020-06-04 | Eingeleitet | Evercore ISI | Outperform |
| 2019-09-24 | Eingeleitet | Goldman | Neutral |
| 2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-24 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-06-24 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-30 | Eingeleitet | Guggenheim | Buy |
| 2018-09-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Krystal Biotech Inc Aktie (KRYS) Neueste Nachrichten
Teacher Retirement System of Texas Purchases 1,369 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Bought by Teacher Retirement System of Texas - Defense World
US High Growth Tech Stocks With Promising Potential - Yahoo Finance
Krystal Biotech: Preparing To Chase Following Positive CHMP Opinion For VYJUVEK - Seeking Alpha
How To Trade (KRYS) - news.stocktradersdaily.com
3 High Growth Companies Insiders Are Betting On - simplywall.st
Krystal Biotech (KRYS) Up 3.3% Since Last Earnings Report: Can It Continue? - Yahoo
Analysts Set Krystal Biotech, Inc. (NASDAQ:KRYS) PT at $220.00 - Defense World
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - Benzinga
Raymond James Financial Inc. Takes $15.99 Million Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Is Krystal Biotech, Inc.'s (NASDAQ:KRYS) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - Simply Wall St
Here's Why Krystal Biotech, Inc. (KRYS) is a Strong Momentum Stock - Yahoo Finance
US Bancorp DE Grows Stake in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech, Inc. (NASDAQ:KRYS) Position Increased by Charles Schwab Investment Management Inc. - Defense World
Krystal Biotech president Suma Krishnan sells $8.9 million in shares By Investing.com - Investing.com South Africa
Krystal Biotech CEO Krishnan sells $8.89 million in stock By Investing.com - Investing.com Australia
Krystal Biotech president Suma Krishnan sells $8.9 million in shares - Investing.com India
Krystal Biotech CEO Krishnan sells $8.89 million in stock - Investing.com
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Keybank National Association OH - Defense World
How to Take Advantage of moves in (KRYS) - news.stocktradersdaily.com
Bank of New York Mellon Corp Has $26.53 Million Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait? - Nasdaq
Krystal Biotech (NASDAQ:KRYS) Earns Buy Rating from Analysts at Jefferies Financial Group - Defense World
Krystal Biotech initiated at buy at Jefferies on Vyjuvek, gene delivery tech - MSN
Krystal Biotech at TD Cowen Conference: Strategic Pipeline Progress By Investing.com - Investing.com Canada
This Krystal Biotech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Krystal Biotech’s Growth Potential: Strong Vyjuvek Launch and Promising Pipeline - TipRanks
Jefferies Initiates Krystal Biotech at Buy With $245 Price Target -March 05, 2025 at 07:22 am EST - Marketscreener.com
Jefferies Initiates Coverage of Krystal Biotech (KRYS) with Buy Recommendation - Nasdaq
Jefferies sets Krystal Biotech stock Buy rating, $245 target By Investing.com - Investing.com Australia
Krystal Biotech initiated with a Buy at Jefferies - TipRanks
Gene Therapy Market Top Companies Study-Krystal Biotech, Inc., - openPR.com
If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today - Benzinga
Is the Market Bullish or Bearish on Krystal Biotech? - Benzinga
KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug - Yahoo Finance
H.C. Wainwright maintains $221 target on Krystal Biotech stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains $221 target on Krystal Biotech stock - Investing.com India
Krystal Biotech’s (KRYS) “Buy” Rating Reiterated at HC Wainwright - Defense World
New York State Common Retirement Fund Has $3.66 Million Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Principal Financial Group Inc. Purchases 3,727 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Krystal gets positive EU regulatory opinion for Vyjuvek - MSN
Krystal Biotech chief accounting officer sells $131,415 in stock - Investing.com India
Krystal Biotech chief accounting officer sells $131,415 in stock By Investing.com - Investing.com UK
Solid Earnings Reflect Krystal Biotech's (NASDAQ:KRYS) Strength As A Business - Yahoo Finance
(KRYS) On The My Stocks Page - Stock Traders Daily
Krystal gets positive EU regulatory opinion for Vyjuvek (KRYS:NASDAQ) - Seeking Alpha
Krystal Biotech’s Vyjuvek: Anticipated European Approval and Strong Sales Projections Drive Buy Rating - TipRanks
European Panel Backs Approval of Topical Gene Therapy, Three Other New Medicines - Marketscreener.com
Krystal Biotech receives positive CHMP opinion for VYJUVEK - TipRanks
Krystal Biotech Gets CHMP Backing for Vyjuvek Approval - MarketWatch
Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa - The Manila Times
Finanzdaten der Krystal Biotech Inc-Aktie (KRYS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.05%
1.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):